(Q39456999)

12 September 2017

title

The immune contexture in cancer prognosis and treatment (English)

1 reference

12 September 2017

4

1 reference

12 September 2017

2

0 references

Catherine Sautès-Fridman

series ordinal

3

object named as

Catherine Sautès-Fridman

0 references

Wolf Hervé Fridman

series ordinal

1

object named as

Wolf H Fridman

0 references

language of work or name

English

0 references

publication date

25 July 2017

1 reference

Nature Reviews Clinical Oncology

12 September 2017

published in

1 reference

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The Basis of Oncoimmunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The Dynamics of Apoptotic Cell Clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Macrophages and therapeutic resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic and predictive impact of intra- and peritumoral immune infiltrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

TLS in Tumors: What Lies Within

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Using tumour phylogenetics to identify the roots of metastasis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

In Situ Mapping of Innate Lymphoid Cells in Human Skin: Evidence for Remarkable Differences between Normal and Inflamed Skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The prognostic landscape of genes and infiltrating immune cells across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Natural and therapy-induced immunosurveillance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Mutational landscape and significance across 12 major cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor-intrinsic oncogene pathways mediating immune avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The host STING pathway at the interface of cancer and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The consensus molecular subtypes of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Microsatellite Instability as a Biomarker for PD-1 Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunogenic cell death and DAMPs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunogenic cell death in cancer and infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Molecular mechanisms of ATP secretion during immunogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Leukocyte composition of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

An immunosurveillance mechanism controls cancer cell ploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunosuppressive activities of adenosine in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Pro-necrotic molecules impact local immunosurveillance in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunological off-target effects of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Antibody therapeutics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Illicit survival of cancer cells during polyploidization and depolyploidization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Landscape of tumor-infiltrating T cell repertoire of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

CANCER IMMUNOLOGY. The "cancer immunogram".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

ICP34.5 protein of herpes simplex virus facilitates the initiation of protein translation by bridging eukaryotic initiation factor 2alpha (eIF2alpha) and protein phosphatase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Hallmarks of Tissue-Resident Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Mouse models in oncoimmunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

CD73 is associated with poor prognosis in HNSCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

CD73 is associated with poor prognosis in high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

PD-L1 Expression and CD8(+) T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Decoding cell death signals in inflammation and immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

7 January 2021

inferred from DOI database lookup

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.101

7 January 2021

inferred from DOI database lookup

Prognostic and predictive markers for the new immunotherapies.

1 reference

12 December 2020

The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research

1 reference

12 December 2020

Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome

1 reference

12 December 2020

Tumour-associated macrophage polarisation and re-education with immunotherapy

1 reference

12 December 2020

10.1038/NRCLINONC.2017.101

Identifiers

DOI

1 reference

12 September 2017

1 reference